Search results for "coagulants"

showing 10 items of 248 documents

Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review an…

2018

Abstract Aims Patients with acute pulmonary embolism (PE) classified as low risk by the Pulmonary Embolism Severity Index (PESI), its simplified version (sPESI), or the Hestia criteria may be considered for early discharge. We investigated whether the presence of right ventricular (RV) dysfunction may aggravate the early prognosis of these patients. Methods and results We did a systematic review and meta-analysis of studies including low-risk patients with acute PE to investigate the prognostic value of RV dysfunction. Diagnosis of RV dysfunction was based on echocardiography or computed tomography pulmonary angiography. In addition, we investigated the prognostic value of elevated troponin…

MaleComputed Tomography AngiographyVentricular Dysfunction Right030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineNatriuretic peptidePulmonary angiographyHospital MortalityRight ventricular dysfunctionAged 80 and overbiologyMortality rateHome treatmentMiddle AgedPrognosisTroponinPulmonary embolismEchocardiographyMeta-analysisAcute DiseaseCardiologyFemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtymedicine.drug_classFast Track Clinical ResearchRisk Assessment03 medical and health sciencesAnticoagulationInternal medicinemedicineHumansMortalityNatriuretic PeptidesRisk stratificationAgedbusiness.industryPulmonary embolismAnticoagulants030229 sport sciencesOdds ratiomedicine.diseaseTroponinConfidence intervalEditor's Choicebiology.proteinbusinessBiomarkersEuropean Heart Journal
researchProduct

Regional anticoagulation with heparin of an extracorporeal CO2 removal circuit: a case report

2019

Abstract Background Extracorporeal carbon dioxide removal is an increasingly used respiratory support technique. As is true of all extracorporeal techniques, extracorporeal carbon dioxide removal needs proper anticoagulation. We report a case of a patient at risk of bleeding complications who was treated with extracorporeal carbon dioxide removal and anticoagulated with a regional technique. Case presentation A 56-year-old Caucasian man with a history of chronic obstructive pulmonary disease exacerbation required extracorporeal carbon dioxide removal for severe hypercapnia and acidosis despite mechanical ventilation. The extracorporeal circuit was anticoagulated using a regional heparin tec…

MaleExtracorporeal CirculationLow platelet countExacerbationmedicine.medical_treatment2lcsh:MedicineCase Report030204 cardiovascular system & hematologyExtracorporealExtracorporeal carbon dioxide removal03 medical and health sciencesContinuous venovenous filtrationPulmonary Disease Chronic Obstructive0302 clinical medicineExtracorporeal CO 2 removalExtracorporeal Membrane OxygenationmedicineHeparin regional anticoagulationHumansAcidosisMechanical ventilationbusiness.industryHeparinMedicine (all)removallcsh:RAnticoagulantsExtracorporeal COGeneral MedicineHeparinExtracorporeal CO2 removalCarbon DioxideMiddle AgedRespiration ArtificialTreatment Outcome030220 oncology & carcinogenesisAnesthesiaDisease Progressionmedicine.symptomContinuous venovenous filtration; Extracorporeal CO ; 2; removal ; Heparin regional anticoagulationbusinessHypercapniamedicine.drugJournal of Medical Case Reports
researchProduct

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

2013

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg onc…

MaleMESH: Factor Xa[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRivaroxabanRandomized controlled triallawMedicineMESH: Double-Blind Method030212 general & internal medicineMESH: AgedMESH: Middle AgedVenous ThromboembolismGeneral MedicineMiddle AgedMESH: Thiophenes3. Good healthAnesthesiaAcute DiseaseMESH: Administration OralMESH: Acute DiseaseFemaleMESH: Hemorrhagemedicine.drugAdultRandomizationMESH: EnoxaparinInjections SubcutaneousMorpholinesMESH: MorpholinesHemorrhageThiophenesMESH: AnticoagulantsMESH: Drug Administration SchedulePlaceboDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodRivaroxaban venous thromboembolismHumansEnoxaparinAgedRivaroxabanMESH: Humansbusiness.industryMESH: Injections SubcutaneousAnticoagulantsMESH: AdultConfidence intervalMESH: MalechemistryBetrixabanRelative riskbusinessVenous thromboembolismMESH: FemaleFactor Xa Inhibitors
researchProduct

Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients

2020

Background and Purpose— We aimed to determine the safety and mortality after mechanical thrombectomy in patients taking vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs). Methods— In a multicenter observational cohort study, we used multiple logistic regression analysis to evaluate associations of symptomatic intracranial hemorrhage (sICH) with VKA or DOAC prescription before thrombectomy as compared with no anticoagulation. The primary outcomes were the rate of sICH and all-cause mortality at 90 days, incorporating sensitivity analysis regarding confirmed therapeutic anticoagulation. Additionally, we performed a systematic review and meta-analysis of literature on this to…

MaleMESH: RegistriesAdministration Oral030204 cardiovascular system & hematology0302 clinical medicineInterquartile rangeMESH: ThrombectomyRegistriesStrokeThrombectomyMESH: AgedMESH: Middle AgedMESH: Follow-Up StudiesMiddle Aged3. Good healthddc:StrokeMESH: Administration OralFemale[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Cardiology and Cardiovascular MedicineMESH: Intracranial HemorrhagesCohort studymedicine.medical_specialty610 Medicine & healthMESH: AnticoagulantsLower riskMESH: Stroke03 medical and health sciencesMeta-Analysis as TopicInternal medicinemedicineHumansMESH: Meta-Analysis as TopicMedical prescriptionAgedAdvanced and Specialized NursingMESH: Humansbusiness.industryAnticoagulantsOdds ratiomedicine.diseaseFactor Xa inhibitorsMESH: MaleStroke treatmentIntracranial hemorrhagesObservational studyNeurology (clinical)MESH: Systematic Reviews as TopicbusinessMESH: Female030217 neurology & neurosurgeryFollow-Up StudiesSystematic Reviews as Topic
researchProduct

Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation

2018

Aims: Although oral anticoagulants (OACs) are effective in preventing stroke in older people with atrial fibrillation (AF), they are often underused in this particularly high-risk population. The aim of the present study was to assess the appropriateness of OAC prescription and its associated factors in hospitalized patients aged 65 years or older. Methods: Data were obtained from the retrospective phase of Simulation-based Technologies to Improve the Appropriate Use of Oral Anticoagulants in Hospitalized Elderly Patients With Atrial Fibrillation (SIM-AF) study, held in 32 Italian internal medicine and geriatric wards. The appropriateness of OAC prescription was assessed, grouping patients …

MaleOralappropriateness of prescriptionappropriateness of prescription atrial fibrillation internal medicine geriatric wards older patients oral anticoagulantSocio-culturaleAdministration OralHemorrhageInappropriate PrescribingDrug Prescriptionsinternal medicine and geriatric wardDose-Response Relationshipolder patientRisk Factorsoral anticoagulant80 and overHumansatrial fibrillationPharmacology (medical)Prospective StudiesAgedRetrospective StudiesAged 80 and overPharmacologygeriatric wardsDose-Response Relationship DrugSettore MED/09 - MEDICINA INTERNAAge FactorsAnticoagulantsinternal medicine and geriatric wardsOriginal Articlesolder patientsappropriateness of prescription; atrial fibrillation; internal medicine and geriatric wards; older patients; oral anticoagulant;appropriateness of prescription; atrial fibrillation; internal medicine and geriatric wards; older patients; oral anticoagulant; Pharmacology; Pharmacology (medical)Strokeinternal medicineappropriateness of prescription; atrial fibrillation; internal medicine and geriatric wards; older patients; oral anticoagulantAdministrationFemaleDrug
researchProduct

Portal Vein Thrombosis in a Preterm Newborn with Mutation of the MTHFR and PAI-1 Genes and Sepsis by Candida parapsilosis

2016

Objective This report discusses the role of both congenital and acquired risk factors in the pathogenesis of portal vein thrombosis (PVT). Study Design We describe the clinical management and treatment of PVT in a preterm newborn with a homozygous mutation of the methylenetetrahydrofolate reductase (MTHFR) and plasminogen activator inhibitor-1 (PAI-1) genes and sepsis by Candida parapsilosis. Results Although literature data suggest a minor role of genetic factors in thrombophilia in the case of only one mutation, we hypothesize that combined thrombophilic genetic defects may have a cumulative effect and significantly increase the thrombotic risk. Conclusion It could be appropriate to incl…

MalePathologymedicine.medical_specialtyCandida parapsilosis030204 cardiovascular system & hematologyBioinformaticsCandida parapsilosisThrombophiliaSepsisPathogenesis03 medical and health sciences0302 clinical medicineSepsis030225 pediatricsPlasminogen Activator Inhibitor 1medicineHumansMethylenetetrahydrofolate Reductase (NADPH2)Venous ThrombosisPolymorphism GeneticbiologyPortal Veinbusiness.industryCandidiasisInfant NewbornAnticoagulantsFactor VObstetrics and Gynecologyportal thrombosis fungal infection gene polymorphismmedicine.diseasebiology.organism_classificationPortal vein thrombosisSurgical Procedures OperativeMethylenetetrahydrofolate reductaseMutationPediatrics Perinatology and Child Healthbiology.proteinGene polymorphismbusinessPlasminogen activatorAmerican Journal of Perinatology
researchProduct

Risk Stratification Using the CHA(2)DS(2)-VASc Score in Takotsubo Syndrome: Data From the Takotsubo Italian Network

2017

Background The CHA 2 DS 2 ‐VASc score predicts stroke in patients with atrial fibrillation and has been reported to have a prognostic role even in acute coronary syndrome patients. The Takotsubo syndrome is a condition that mimics acute coronary syndrome and may present several complications including stroke. We sought to assess the ability of CHA 2 DS 2 ‐VASc score to predict adverse events in Takotsubo syndrome patients. Methods and Results Overall, 371 Takotsubo syndrome patients were enrolled in a prospective registry. Patients were divided into 3 groups according to the CHA 2 DS 2 ‐VASc score: Group A (≤1), B (2–3), and C (≥4). The median CHA 2 DS 2 ‐VASc score was 3 (interquartile ra…

MalePediatricsArrhythmias030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk FactorsInterquartile rangeOdds RatioCoronary Heart DiseaseProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionDSStrokeTakotsuboOriginal ResearchIncidenceMortality rateanticoagulant cardiovascular events CHA2DS2-VASc score stroke Takotsubo Takotsubo cardiomyopathy. Takotsubo syndromeAtrial fibrillationMiddle AgedPrognosisAnticoagulant; Cardiovascular events; CHA2DS2-VASc score; Stroke; Takotsubo; Takotsubo cardiomyopathy; Takotsubo syndrome; Cardiology and Cardiovascular MedicineStrokeItalyCardiologyFemaleCHA2DS2‐VASc scoreTakotsubo syndromeCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute coronary syndromeCHA2DS2-VASc scoreCardiomyopathy2Cardiovascular eventRisk Assessment-VASc scorecardiovascular events03 medical and health sciencesInternal medicinemedicineHumansAgedbusiness.industryAnticoagulantAnticoagulantsThrombosisOdds ratiomedicine.diseaseCHA2DS2–VASc scoreCHACerebrovascular Disease/StrokeTakotsubo cardiomyopathybusinessFollow-Up Studies
researchProduct

Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies

2016

Introduction A paucity of data exists on the incidence, diagnosis and treatment of bleeding in women with inherited factor VII (FVII) deficiency. Aim Here we report results of a comprehensive analysis from two international registries of patients with inherited FVII deficiency, depicting the clinical picture of this disorder in women and describing any gender-related differences. Methods A comprehensive analysis of two fully compatible, international registries of patients with inherited FVII deficiency (International Registry of Factor VII deficiency, IRF7; Seven Treatment Evaluation Registry, STER) was performed. Results In our cohort (N = 449; 215 male, 234 female), the higher prevalence…

MalePediatricsFactor VII Deficiency030204 cardiovascular system & hematologyCohort Studieschemistry.chemical_compound0302 clinical medicineAntifibrinolytic agentgynaecological bleedingRegistriesChildGenetics (clinical)Aged 80 and overFactor VIIIncidence (epidemiology)Hazard ratio[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineFactor VIIMiddle AgedAntifibrinolytic AgentsRecombinant Proteins3. Good healthPhenotypeTreatment OutcomeChild PreschoolCohortFemalewomengynaecological bleeding; inherited factor VII deficiency; recombinant activated factor VII; womenCohort studyAdultmedicine.medical_specialtyAdolescentMucocutaneous zoneHemorrhageFactor VIIaYoung Adult03 medical and health sciencesmedicineHumansMenorrhagiaAgedProportional Hazards ModelsCoagulantsbusiness.industryProportional hazards modelInfantrecombinant activated factor VIISurgeryROC Curvechemistryinherited factor VII deficiencybusiness030215 immunology
researchProduct

Estimated prevalence of undiagnosed atrial fibrillation in the United States.

2017

Introduction As atrial fibrillation (AF) is often asymptomatic, it may remain undiagnosed until or even after development of complications, such as stroke. Consequently the observed prevalence of AF may underestimate total disease burden. Methods To estimate the prevalence of undiagnosed AF in the United States, we performed a retrospective cohort modeling study in working age (18-64) and elderly (≥65) people using commercial and Medicare administrative claims databases. We identified patients in years 2004-2010 with incident AF following an ischemic stroke. Using a back-calculation methodology, we estimated the prevalence of undiagnosed AF as the ratio of the number of post-stroke AF patie…

MalePediatricsSocial Scienceslcsh:MedicineBlood Pressure030204 cardiovascular system & hematologyVascular Medicine0302 clinical medicineElderlyEndocrinologyRisk FactorsEpidemiologyAtrial FibrillationPrevalenceMedicine and Health Sciences030212 general & internal medicineYoung adultlcsh:ScienceStrokeAged 80 and overeducation.field_of_studyMultidisciplinaryData CollectionAtrial fibrillationMiddle AgedStrokeHemorrhagic StrokeNeurologyHypertensionFemalemedicine.symptomArrhythmiaResearch ArticleAdultmedicine.medical_specialtyAdolescentEndocrine DisordersCerebrovascular DiseasesPolitical SciencePopulationCardiologyPublic PolicyMedicareAsymptomaticRisk Assessment03 medical and health sciencesYoung AdultmedicineDiabetes MellitusHumanseducationDisease burdenAgedProbabilityRetrospective StudiesIschemic Strokebusiness.industrylcsh:RAnticoagulantsRetrospective cohort studymedicine.diseaseUnited StatesAge GroupsGeriatricsMetabolic DisordersPeople and PlacesPopulation Groupingslcsh:QbusinessPLoS ONE
researchProduct

e-Health-based management of patients receiving oral anticoagulation therapy: results from the observational thrombEVAL study

2017

Essentials e-Health based health care by an expert centre may advance management of oral anticoagulation. Outcome of patients was compared between an e-health based coagulation service and regular care. Patients in the coagulation service cohort experienced a significantly better clinical outcome. Lower risk for adverse events was related to anticoagulation-specific and non-specific outcome. SummaryBackground Management of oral anticoagulation (OAC) therapy is essential to minimize adverse events in patients receiving vitamin K-antagonists (VKAs). Data on the effect of e-health-based anticoagulation management systems on the clinical outcome of OAC patients are limited. Objectives To compar…

MalePediatricsVitamin KAdministration OralComorbidity030204 cardiovascular system & hematologyRate ratioSERVICE0302 clinical medicineRisk FactorsGermanyUSUAL MEDICAL-CAREClinical endpointProspective Studies030212 general & internal medicineAged 80 and overOUTCOMESHazard ratioDABIGATRANHematologyMiddle AgedHospitalizationTreatment OutcomeCohortdelivery of healthcareFemaleepidemiologyPatient SafetytelemedicineCohort studymedicine.drugmedicine.medical_specialtyanticoagulantsHemorrhageLower riskpatient outcome assessmentWARFARIN03 medical and health sciencesThromboembolismmedicineNONVALVULAR ATRIAL-FIBRILLATIONHumansQUALITYInternational Normalized RatioAdverse effectBlood CoagulationMETAANALYSISAgedProportional Hazards ModelsRivaroxabanbusiness.industrySTROKE PREVENTIONRIVAROXABANbusinessFollow-Up Studies
researchProduct